COMMUNIQUÉS West-GlobeNewswire

-
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
16/06/2025 -
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer
16/06/2025 -
PetMed Express, Inc. Announces Preliminary Fourth Quarter and FY 2025 Results and Filing of Form 12b-25
16/06/2025 -
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
16/06/2025 -
Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
16/06/2025 -
SS Innovations Announces Successful Completion of First Robotic Cardiac Surgery in the Western Hemisphere Utilizing the Company’s SSi Mantra 3 Surgical Robotic System
16/06/2025 -
Solera HALO™ Platform Adds Rapid Configurability Tool for Integrated Digital Health Networks
16/06/2025 -
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
16/06/2025 -
Bon Natural Life Announces Distribution Agreement with Tianjin Merrill-Youli Trading Co., Ltd.
16/06/2025 -
3Daughters to Lead Panel at BIO International Convention on Patient Reported Outcomes that Includes FDA Division Director
16/06/2025 -
INVO Fertility’s Wisconsin Clinic Recognized on Newsweek’s List of America’s Best Fertility Clinics for 2025
16/06/2025 -
Psychemedics Releases 2025 Workforce Insights Report
16/06/2025 -
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
16/06/2025 -
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
16/06/2025 -
BlueGenes and Levrx Partner to Integrate Real-Time Genetic Insights into the Pharmacy Benefit Experience
16/06/2025 -
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
16/06/2025 -
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
16/06/2025 -
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
16/06/2025 -
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
16/06/2025
Pages